-$0.85 EPS Expected for Prothena Co. plc (NASDAQ:PRTA) This Quarter

Analysts predict that Prothena Co. plc (NASDAQ:PRTAGet Rating) will post earnings of ($0.85) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Prothena’s earnings. The highest EPS estimate is ($0.78) and the lowest is ($0.94). Prothena posted earnings per share of ($0.91) during the same quarter last year, which would indicate a positive year over year growth rate of 6.6%. The company is expected to announce its next earnings results after the market closes on Monday, January 1st.

On average, analysts expect that Prothena will report full year earnings of ($2.48) per share for the current fiscal year, with EPS estimates ranging from ($3.55) to ($1.10). For the next financial year, analysts anticipate that the firm will post earnings of ($1.90) per share, with EPS estimates ranging from ($3.41) to ($0.39). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Prothena.

Prothena (NASDAQ:PRTAGet Rating) last released its quarterly earnings data on Thursday, February 17th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.03. Prothena had a return on equity of 18.11% and a net margin of 33.39%. The firm had revenue of $1.17 million during the quarter, compared to analyst estimates of $0.28 million. During the same period in the prior year, the company posted ($0.77) earnings per share.

Several research firms have weighed in on PRTA. Zacks Investment Research upgraded Prothena from a “sell” rating to a “hold” rating and set a $35.00 price objective on the stock in a research report on Wednesday, April 20th. StockNews.com started coverage on Prothena in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Citigroup lowered their price target on shares of Prothena from $87.00 to $73.00 in a report on Friday, February 18th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Prothena presently has a consensus rating of “Buy” and an average price target of $64.73.

In related news, Director Richard T. Collier sold 5,000 shares of the firm’s stock in a transaction on Tuesday, April 5th. The stock was sold at an average price of $39.41, for a total value of $197,050.00. Following the completion of the sale, the director now directly owns 1,219 shares in the company, valued at $48,040.79. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 31.20% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. Denali Advisors LLC purchased a new stake in Prothena during the 4th quarter valued at about $40,000. Allegheny Financial Group LTD acquired a new stake in shares of Prothena in the fourth quarter valued at $49,000. Spire Wealth Management increased its position in shares of Prothena by 938.8% during the fourth quarter. Spire Wealth Management now owns 1,070 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 967 shares during the period. Advisor Group Holdings Inc. raised its holdings in shares of Prothena by 1,129.1% in the 3rd quarter. Advisor Group Holdings Inc. now owns 1,438 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 1,321 shares in the last quarter. Finally, Macquarie Group Ltd. acquired a new stake in Prothena during the third quarter worth approximately $110,000. 92.64% of the stock is owned by hedge funds and other institutional investors.

NASDAQ PRTA traded down $0.21 during trading hours on Tuesday, reaching $30.42. 2,369 shares of the company’s stock were exchanged, compared to its average volume of 388,958. The company’s 50-day moving average is $34.83 and its two-hundred day moving average is $42.27. Prothena has a one year low of $21.30 and a one year high of $79.75. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 27.91 and a beta of 1.37.

About Prothena (Get Rating)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

Read More

Get a free copy of the Zacks research report on Prothena (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.